Phytochemicals from peanut (Arachis hypogaea L.) skin extract with potential for pharmacological activity

2021 ◽  
Vol 17 ◽  
Author(s):  
Sampson Kofi Kyei ◽  
William Iheanyi Eke ◽  
Hajara Abdul-Karim ◽  
Godfred Darko ◽  
Onyewuchi Akaranta
Keyword(s):  
Phenolic Compounds ◽  
Biologically Active ◽  
Leafy Vegetables ◽  
Skin Extract ◽  
Pharmacological Activities ◽  
In Vivo Models ◽  
The Past ◽  
Peanut Skin ◽  
Peanut Skins

Background: Plant phenolics, commonly present in legumes, leafy vegetables, fruits, grains are a key source of bioactive nutrients existing as flavonols, flavanones, flavanols, phytosterols, among others. Peanuts, being crops of high commercial use, undergo processing that generates voluminous agro-wastes. The waste comprises both the shells and skins, which could be valorized. Its versatile functionality has encouraged extensive research into peanut skin-derived chemicals for diverse applications over the past few decades. Peanut skin, however, is ascertained to be rich in flavonoids, stilbenes (resveratrol), and other phenolic compounds. Methods: This review presents the biologically active compounds and pharmacological activities of peanut skins and their related works over the past few years. Articles carefully chosen from broad databases such as Scopus, Science Direct, Pub Med, SciFinder, among others, were used as the primary data. Results: The bioactive components of peanut skin extracts exhibit anti-oxidant, anti-inflammatory, anti-bacterial, anti-viral, anti-fungal, anti-cancer/anti-tumour, anti-cardiovascular, and anti-diabetes/obesity activities via in vitro and in vivo models. Besides, their varied biological properties make them potential precursors for the management of diverse diseases and ailments. Potential applications: Phytochemicals from peanut skins could be deployed as an antioxidant, antidiabetic and antimicrobial agents in drugs for the clinical treatment of ailments with extensive clinical applications. Conclusion: The present review covers the chemistry and pharmacological activities of peanut skin phytochemicals. Our findings in this review substantiate the importance of peanut skin extracts and their varied potential for the treatment of specific diseases. The results indicate that they are attractive target compounds for the development of new drugs. We hope that this information will inform further in vivo studies on the role of peanut skin phenolic compounds in our health.

An Overview on Phytochemical and Pharmacological Profile of Morus alba Linn.

2020 ◽  
Vol 16 ◽  
Author(s):  
Arpita Paul ◽  
Monami Rajiung ◽  
Kamaruz Zaman ◽  
Sushil Kumar Chaudhary ◽  
Hans Raj Bhat ◽  
...  
Keyword(s):  
Traditional Medicine ◽  
Morus Alba ◽  
Biologically Active ◽  
Pharmacological Profile ◽  
Pharmacological Activities ◽  
Significant Information ◽  
The Past ◽  
Comprehensive Information ◽  
The Family ◽  
White Mulberry

Background: Morus alba Linn. commonly known as white mulberry, belongs to the family Moraceae, is a promising traditional medicine. In Asia, besides its use in the preparation of delicacies, every part of this plant is utilized in traditional medicine. Over the past decade, studies related to identification and isolation of biologically active compounds, with flavonoids as the major class of phytoconstituents, from this plant has been reported. These phytoconstituents are not only found to be beneficial for the maintenance of general health but also are associated with a range of potential pharmacological activities such as antioxidant, anti-inflammatory, anti-diabetic, anticancer, hepatoprotective, cardioprotective, neuroprotective to name a few. Objective: This review aims to provide upgraded and comprehensive information regarding the phytochemical, ethnomedicinal use and pharmacological profile of the plant Morus alba Linn. Method: The significant information has been collected through various database viz. PubMed, Scopus, Web of Science, Science Direct based on the recent findings, using different terms of Morus alba. Results: The outcome of the study suggests that Morus alba is a multifunctional plant numerous phytochemicals, and possess a range of pharmacological activities. Conclusion: The data assembled on Morus alba will be beneficial to trigger research in various fields of pharmaceutical and allied science to explore the medicinal importance of this unique plant.

Phytochemicals as Potential Inhibitors of Advanced Glycation End Products: Health Aspects and Patent Survey

2021 ◽  
Vol 12 ◽  
Author(s):  
Annayara C. F. Fernandes ◽  
Jeane B. Melo ◽  
Vanize M. Genova ◽  
Ádina L. Santana ◽  
Gabriela Macedo
Keyword(s):  
Phenolic Compounds ◽  
Inflammatory Responses ◽  
Low Cost ◽  
Advanced Glycation Endproducts ◽  
Advanced Glycation ◽  
Glycation Endproducts ◽  
Synthetic Drugs ◽  
Peanut Skins

Background: Glycation is a chemical reaction that synthesize advanced glycation endproducts (AGEs). The AGEs irreversibly damage macromolecules present in tissues and organs, leading to the impairment of biological functions. For instance, the accumulation of AGEs induces oxidative stress and consequently inflammatory responses in human body, leading to the on set/worsening of diseases, including obesity, asthma, cognitive impairment, and cancer. There is a current demand on natural and low-cost sources of antiglycant agents. As a result, food phytochemicals presented promising results to inhibit glycation and consequently, the formation of AGEs. Objective: Here, we describe the mechanism of glycation on the worsening of diseases, the methods os detection, and the current findings on the use of phytochemicals (phenolic compounds, phytosterols, carotenoids, terpenes and vitamins) as natural therapeuticals to inhibit health damages via inhibition of AGEs in vitro and in vivo. Methods: This manuscript reviewed publications available in the PubMed and Science Direct databases dated from the last 20 years on the uses of phytochemicals to inhibit the AGEs in vitro and in vivo. Also, recent patents on the use of anti-glycant drugs were reviewed using the Google Advanced Patents database. Results and Discussion: Phenolic compounds have been mostly studied to inhibit AGEs. Food phytochemicals derived from agroindustry wastes, including peanut skins, and the bagasses derived from citrus and grapes are promising antiglycant agents via scavenging of free radicals, metal ions, the suppression of metabolic pathways that induces inflammation, the activation of pathways that promote antioxidant defense, the blocking of AGE connection with the receptor for advanced glycation endproducts (RAGE). Conclusion: Phytochemicals derived from agroindustry are promising anti-glycants, which can be included to replace synthetic drugs for AGE inhibition, and consequently to act as a therapeutical strategy to prevent and treat diseases caused by AGEs, including diabetes, ovarian cancer, osteoporosis, and Alzheimer’s disease.

scholarly journals TACO and TRALI: biology, risk factors, and prevention strategies

Hematology ◽  
2018 ◽  
Vol 2018 (1) ◽  
pp. 585-594 ◽  
Author(s):  
Nareg Roubinian
Keyword(s):  
Risk Factors ◽  
Mitigation Strategies ◽  
Blood Component ◽  
Patient Blood Management ◽  
Blood Management ◽  
Prevention Strategies ◽  
In Vivo Models ◽  
The Past ◽  
Circulatory Overload

AbstractTransfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO) are the leading causes of transfusion-related morbidity and mortality. These adverse events are characterized by acute pulmonary edema within 6 hours of a blood transfusion and have historically been difficult to study due to underrecognition and nonspecific diagnostic criteria. However, in the past decade, in vivo models and clinical studies utilizing active surveillance have advanced our understanding of their epidemiology and pathogenesis. With the adoption of mitigation strategies and patient blood management, the incidence of TRALI and TACO has decreased. Continued research to prevent and treat these severe cardiopulmonary events is focused on both the blood component and the transfusion recipient.

scholarly journals In Vitro and In Vivo Models to Study the Zoonotic Mosquito-Borne Usutu Virus

Viruses ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 1116
Author(s):  
Emna Benzarti ◽  
Mutien Garigliany
Keyword(s):  
Animal Health ◽  
Neurological Complications ◽  
Lessons Learned ◽  
In Vivo Models ◽  
Usutu Virus ◽  
The Past ◽  
Experimental Systems ◽  
Human Infections

Usutu virus (USUV), a mosquito-borne zoonotic flavivirus discovered in South Africa in 1959, has spread to many European countries over the last 20 years. The virus is currently a major concern for animal health due to its expanding host range and the growing number of avian mass mortality events. Although human infections with USUV are often asymptomatic, they are occasionally accompanied by neurological complications reminiscent of those due to West Nile virus (another flavivirus closely related to USUV). Whilst USUV actually appears less threatening than some other emergent arboviruses, the lessons learned from Chikungunya, Dengue, and Zika viruses during the past few years should not be ignored. Further, it would not be surprising if, with time, USUV disperses further eastwards towards Asia and possibly westwards to the Americas, which may result in more pathogenic USUV strains to humans and/or animals. These observations, inviting the scientific community to be more vigilant about the spread and genetic evolution of USUV, have prompted the use of experimental systems to understand USUV pathogenesis and to boost the development of vaccines and antivirals. This review is the first to provide comprehensive coverage of existing in vitro and in vivo models for USUV infection and to discuss their contribution in advancing data concerning this neurotropic virus. We believe that this paper is a helpful tool for scientists to identify gaps in the knowledge about USUV and to design their future experiments to study the virus.

O4-01-03: Phenolic compounds inhibit Aβ aggregation and prevent Alzheimer pathology in in vitro and in vivo models

2010 ◽  
Vol 6 ◽  
pp. S150-S151
Author(s):  
Masahito Yamada ◽  
Kenjiro Ono ◽  
Tsuyoshi Hamaguchi ◽  
Mie Hirohata ◽  
Akiyoshi Morinaga ◽  
...  
Keyword(s):  
Phenolic Compounds ◽  
In Vivo Models ◽  
Aβ Aggregation ◽  
Alzheimer Pathology

scholarly journals Induction of Fetal Hemoglobin By FTX6058, a Novel Small Molecule Development Candidate

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 1-1
Author(s):  
Peter Rahl ◽  
Ivan Efremov ◽  
Billy Stuart ◽  
Keqiang Xie ◽  
Mark Roth ◽  
...  
Keyword(s):  
Small Molecule ◽  
Plasma Concentrations ◽  
Fetal Hemoglobin ◽  
Target Engagement ◽  
Publicly Traded ◽  
In Vivo Models ◽  
Α Subunit ◽  
The Past

Red blood cell disorders like Sickle Cell Disease (SCD) and β-thalassemias are caused by mutations within the gene for the hemoglobin β (HBβ) subunit. A fetal ortholog of HBβ, hemoglobin γ (HBγ) can prevent or reduce disease-related pathophysiology in these disorders by forming nonpathogenic complexes with the required hemoglobin α-subunit. Globin expression is developmentally regulated, with a reduction in production of the fetal ortholog (γ)occurring shortly after birth and a concomitant increase in the levels of the adult ortholog (β). It has been postulated that maintaining expression of the anti-sickling γ ortholog may be of therapeutic benefit in children and adults with SCD. Indeed, individuals with the SCD mutation who also have genetic variants that maintain HBγ expression at clinically meaningful levels do not present with SCD-related symptoms. Parallel target identification efforts using CRISPR and the Fulcrum proprietary, annotated chemical probe screening set in HUDEP2 cells identified a protein complex as a key regulator of HbF expression. Structure-guided medicinal chemistry optimization led to the design of FTX-6058, a novel, potent and selective small molecule with desirable DMPK properties suitable for clinical testing. FTX-6058 treatment of differentiated primary CD34+ cells from multiple healthy donors demonstrated target engagement and potent upregulation of HBG1/2 mRNA and HbF protein. Across multiple healthy and SCD donors, FTX-6058 treatment resulted in a clinically desirable globin profile (e.g., up to 30% absolute HbF) accompanied by pancellular HbF expression, resembling the phenotype of SCD mutation carriers with hereditary persistence of fetal hemoglobin. FTX-6058 demonstrated a superior pharmacological profile relative to hydroxyurea and other small molecule compounds whose putative mechanism of action is to induce HbF. FTX-6058 treatment resulted in robust target engagement and subsequent elevation of the endogenous mouse Hbb-bh1 mRNA in wildtype CD-1 mice and, importantly, also elevation of the human HBG1 mRNA and HbF protein in the Townes SCD mouse model. Preclinical studies using a variety of in vitro and in vivo models have demonstrated the potential of FTX-6058 as a novel HbF-inducing small molecule that could be beneficial to patients with SCD and β-thalassemias. FTX-6058 was shown to be potent and selective in vitro, was well tolerated and elicited a desirable exposure-response relationship in multiple preclinical rodent models with once-a-day oral dosing and at plasma concentrations predicted to be achievable in patients. IND enabling studies for FTX-6058 have been completed. Disclosures Rahl: Fulcrum Therapeutics: Ended employment in the past 24 months. Efremov:Fulcrum Therepeutics: Current Employment, Current equity holder in publicly-traded company. Stuart:Fulcrum Therapeutics: Current Employment, Current equity holder in publicly-traded company. Xie:Fulcrum Therapeutics: Current Employment. Roth:Fulcrum Therepeutics: Current Employment, Current equity holder in publicly-traded company. Barnes:Fulcrum Therapeutics: Ended employment in the past 24 months. Appiah:Fulcrum Therapeutics: Current equity holder in publicly-traded company, Ended employment in the past 24 months. Peters:Fulcrum Therapeutics: Current Employment. Li:Fulcrum Therapeutics: Ended employment in the past 24 months. Kazmirski:Fulcrum Therapeutics: Ended employment in the past 24 months. Bruno:Fulcrum Therapeutics: Current Employment. Stickland:Fulcrum Therepeutics: Current Employment, Current equity holder in publicly-traded company. Ronco:Fulcrum Therepeutics: Current Employment, Current equity holder in publicly-traded company. Cadavid:Fulcrum Therapeutics: Current Employment, Current equity holder in publicly-traded company. Thompson:Fulcrum Therepeutics: Current Employment, Current equity holder in publicly-traded company. Wallace:Fulcrum Therepeutics: Current Employment, Current equity holder in publicly-traded company. Moxham:Fulcrum Therepeutics: Current Employment, Current equity holder in publicly-traded company.

scholarly journals Sea Buckthorn and Rosehip Oils with Chokeberry Extract to Prevent Hypercholesterolemia in Mice Caused by a High-Fat Diet In Vivo

Nutrients ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 2941
Author(s):  
Lubov Tereshchuk ◽  
Kseniya Starovoytova ◽  
Olga Babich ◽  
Lyubov Dyshlyuk ◽  
Irina Sergeeva ◽  
...  
Keyword(s):  
Blood Serum ◽  
Dietary Supplement ◽  
Full Range ◽  
Antioxidant Properties ◽  
Hepatoprotective Activity ◽  
Sea Buckthorn ◽  
Biologically Active ◽  
Laboratory Animals ◽  
In Vivo Models

Dietary supplementation based on sea buckthorn and rosehip oils with added chokeberry extract was studied. We added the dietary supplement to the feed mixtures for laboratory animals. The possible toxicological effects and hypocholesterolemic, hepatoprotective activity of the dietary supplement in vivo were studied. After the observation period (6 weeks), no significant changes were found in the mass of organs and blood serum of laboratory animals (p > 0.05). However, there was a decrease in hypercholesterolemic indicators. Regular consumption of sea buckthorn and rosehip oils with added chokeberry extract (dietary supplement “ESB-1”) by laboratory animals inhibited the activity of liver enzymes and increased the antioxidant activity of blood serum (after the subcutaneous injection of sunflower oil/oil solution of carbon tetrachloride) but was not sufficient to bring them to physiological standards. The hypocholesterolemic and antioxidant properties of our dietary supplement already allow us to consider it a component of functional food products or a dietary supplement base. However, the full range of its biologically active properties, including the hepatoprotective function and regulation of metabolic disorders, has not been studied yet, which sets the direction of further research in vivo models and clinical practice to confirm its effectiveness in humans.

scholarly journals Delivery of Nucleic Acids and Nanomaterials by Cell-Penetrating Peptides: Opportunities and Challenges

2015 ◽  
Vol 2015 ◽  
pp. 1-16 ◽  
Author(s):  
Yue-Wern Huang ◽  
Han-Jung Lee ◽  
Larry M. Tolliver ◽  
Robert S. Aronstam
Keyword(s):  
Nucleic Acids ◽  
Biomedical Applications ◽  
Cell Penetrating Peptides ◽  
Biologically Active ◽  
The Past ◽  
Cell Penetrating ◽  
Cellular Entry

Many viral and nonviral systems have been developed to aid delivery of biologically active molecules into cells. Among these, cell-penetrating peptides (CPPs) have received increasing attention in the past two decades for biomedical applications. In this review, we focus on opportunities and challenges associated with CPP delivery of nucleic acids and nanomaterials. We first describe the nature of versatile CPPs and their interactions with various types of cargoes. We then discussin vivoandin vitrodelivery of nucleic acids and nanomaterials by CPPs. Studies on the mechanisms of cellular entry and limitations in the methods used are detailed.

scholarly journals A Review of the Pharmacological Activities and Recent Synthetic Advances of γ-Butyrolactones

2021 ◽  
Vol 22 (5) ◽  
pp. 2769
Author(s):  
Joonseong Hur ◽  
Jaebong Jang ◽  
Jaehoon Sim
Keyword(s):  
Natural Products ◽  
Total Synthesis ◽  
Small Molecules ◽  
Biologically Active ◽  
Synthetic Methods ◽  
Pharmacological Activities ◽  
New Developments ◽  
The Past ◽  
Privileged Structures ◽  
Significant Attention

γ-Butyrolactone, a five-membered lactone moiety, is one of the privileged structures of diverse natural products and biologically active small molecules. Because of their broad spectrum of biological and pharmacological activities, synthetic methods for γ-butyrolactones have received significant attention from synthetic and medicinal chemists for decades. Recently, new developments and improvements in traditional methods have been reported by considering synthetic efficiency, feasibility, and green chemistry. In this review, the pharmacological activities of natural and synthetic γ-butyrolactones are described, including their structures and bioassay methods. Mainly, we summarize recent advances, occurring during the past decade, in the construction of γ-butyrolactone classified based on the bond formation in γ-butyrolactone between (i) C5-O1 bond, (ii) C4-C5 and C2-O1 bonds, (iii) C3-C4 and C2-O1 bonds, (iv) C3-C4 and C5-O1 bonds, (v) C2-C3 and C2-O1 bonds, (vi) C3-C4 bond, and (vii) C2-O1 bond. In addition, the application to the total synthesis of natural products bearing γ-butyrolactone scaffolds is described.

In vivo Antitumor, Pharmacological and Toxicological Study of Pyrim-ido[4′,5′:4,5]thieno(2,3-b)quinoline with 9-hydroxy-4-(3-diethylaminopropylamino) and 8-methoxy-4-(3-diethylaminopropylamino) Substitutions

2021 ◽  
Vol 21 ◽  
Author(s):  
Hulihalli N. KiranKumar ◽  
Heggodu G. RohitKumar ◽  
Ajay S. Khandagale ◽  
Gopal M. Advirao
Keyword(s):  
Antitumor Activity ◽  
Tumor Regression ◽  
Antioxidant Property ◽  
The Body ◽  
Pharmacological Activities ◽  
In Vivo Models ◽  
Tumor Bearing ◽  
Anti Inflammatory ◽  
Analgesic Activities

Background: We previously synthesized two DNA intercalative pyrimido[4’,5’:4,5]thieno(2,3-b) quinolines (PTQ), 9-hydroxy-4-(3-diethylaminopropylamino)pyrimido[4’,5’:4,5]thieno(2,3-b) quinolines (Hydroxy-DPTQ) and 8-methoxy-4-(3-diethylaminopropylamino) pyrimido[4’,5’:4,5]thieno(2,3-b) quinolines (Methoxy-DPTQ), and reported their cytotoxicity against cancer cell lines. Objective: In the present study, we sought to analyze the antitumor activity of Hydroxy-DPTQ and Methoxy-DPTQ on Ehrlich’s ascites carcinoma in vivo models, along with other pharmacological activities and toxicity. Methods: Antitumor activity, In vivo antioxidant measurement, Anti-inflammatory activity Analgesic activity, Hematological study, Biochemical parameters, and Nephroprotective ac-tivity. Results: In this study, both the test molecules studied possess potent in vivo antitumor activity without any hematological, biochemical or nephrotoxicity. Significant tumor regression was observed after treatment with both the test molecules, which is suggested by the decrease in the body weight of tumor bearing mice. Mean survival time of mice with tumor was increased from 16 days to 25 and 29 days after 40 and 80 mg/kg Hydroxy-DPTQ treatment, respectively, with a similar result for Methoxy-DPTQ. A dose dependent increase in lifespan upto 80-85% was also displayed by both Hydroxy-DPTQ and Methoxy-DPTQ. Reduction in the tumor volume of mice, upon treatment with molecules also confirmed their antitumor ac-tivity. These molecules also exhibited pharmacological activities such as antioxidant, anti-inflammatory and analgesic activities. Administration of Hydroxy-DPTQ and Methoxy-DPTQ not only reduced the level of lipid peroxidation in tumor bearing mice, but also re-stored the superoxide dismutase, glutathione and catalase levels to normal, substantiating the antioxidant property. Also, treatment of Hydroxy-DPTQ and Methoxy-DPTQ inhibited the pain to approximately 60-80% and 19-33%, respectively. Further, the treatment with Hy-droxy-DPTQ and Methoxy-DPTQ reversed the abnormality in the RBC, WBC and haemo-globin levels, and gentamicin induced nephrotoxicity. Conclusion : Hydroxy-DPTQ and Methoxy-DPTQ are good antitumor molecules with pharmacological properties.

Sign in / Sign up

Export Citation Format

Share Document